Literature DB >> 21195346

Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.

Noriyoshi Kurihara1, Yuko Hiruma, Kei Yamana, Laëtitia Michou, Côme Rousseau, Jean Morissette, Deborah L Galson, Jumpei Teramachi, Hua Zhou, David W Dempster, Jolene J Windle, Jacques P Brown, G David Roodman.   

Abstract

Paget's disease (PD) is characterized by abnormal osteoclasts (OCL) that secrete high <span class="Gene">IL-6 levels and induce exuberant bone formation. Because measles virus nucleocapsid gene (MVNP) and the p62(P392L) mutation are implicated in PD, marrows from 12 PD patients harboring p62(P392L) and eight normals were tested for MVNP expression and pagetic OCL formation. Eight out of twelve patients expressed MVNP and formed pagetic OCL in vitro, which were inhibited by antisense-MVNP. Four out of twelve patients lacked MVNP and formed normal OCL that were hyperresponsive to RANKL but unaffected by antisense-MVNP. Similarly, mice expressing only p62(P394L) formed normal OCL, while mice expressing MVNP in OCL, with or without p62(P394L), developed pagetic OCL and expressed high IL-6 levels dependent on p38MAPK activation. IL-6 deficiency in MVNP mice abrogated pagetic OCL development in vitro. Mice coexpressing MVNP and p62(P394L) developed dramatic Paget's-like bone lesions. These results suggest that p62(P394L) and IL-6 induction by MVNP play key roles in PD. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21195346      PMCID: PMC3025409          DOI: 10.1016/j.cmet.2010.12.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  30 in total

Review 1.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

2.  Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone.

Authors:  Jean Morissette; Nancy Laurin; Jacques P Brown
Journal:  J Bone Miner Res       Date:  2006-12       Impact factor: 6.741

3.  (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.

Authors:  Seiichi Ishizuka; Noriyoshi Kurihara; Sakamuri V Reddy; Jillian Cornish; Tim Cundy; G David Roodman
Journal:  Endocrinology       Date:  2004-12-23       Impact factor: 4.736

4.  Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.

Authors:  Giuseppe Mossetti; Domenico Rendina; Gianpaolo De Filippo; Roberto Viceconti; Gilda Di Domenico; Michele Cioffi; Loredana Postiglione; Vincenzo Nunziata
Journal:  Bone       Date:  2005-03       Impact factor: 4.398

5.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.

Authors:  Sara K Custer; Manuela Neumann; Hongbo Lu; Alexander C Wright; J Paul Taylor
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

6.  Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Hua Zhou; Mark A Subler; David W Dempster; Frederick R Singer; Sakamuri V Reddy; Helen E Gruber; Jolene J Windle; G David Roodman
Journal:  J Clin Invest       Date:  2006-12-21       Impact factor: 14.808

7.  SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone.

Authors:  Luigi Gennari; Fernando Gianfrancesco; Marco Di Stefano; Domenico Rendina; Daniela Merlotti; Teresa Esposito; Salvatore Gallone; Pina Fusco; Innocenzo Rainero; Pierpaola Fenoglio; Maria Mancini; Giuseppe Martini; Simona Bergui; Gianpaolo De Filippo; Giancarlo Isaia; Pasquale Strazzullo; Ranuccio Nuti; Giuseppe Mossetti
Journal:  J Bone Miner Res       Date:  2010-06       Impact factor: 6.741

8.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

9.  Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice.

Authors:  Noriyoshi Kurihara; Hua Zhou; Sakamuri V Reddy; Veronica Garcia Palacios; Mark A Subler; David W Dempster; Jolene J Windle; G David Roodman
Journal:  J Bone Miner Res       Date:  2005-11-21       Impact factor: 6.741

10.  DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells.

Authors:  Mitsuru Yagi; Takeshi Miyamoto; Yumi Sawatani; Katsuya Iwamoto; Naobumi Hosogane; Nobuyuki Fujita; Kozo Morita; Ken Ninomiya; Toru Suzuki; Kana Miyamoto; Yuichi Oike; Motohiro Takeya; Yoshiaki Toyama; Toshio Suda
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

View more
  37 in total

1.  Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo.

Authors:  Kazuaki Miyagawa; Yasuhisa Ohata; Jesus Delgado-Calle; Jumpei Teramachi; Hua Zhou; David D Dempster; Mark A Subler; Jolene J Windle; John M Chirgwin; G David Roodman; Noriyoshi Kurihara
Journal:  JCI Insight       Date:  2020-03-26

Review 2.  p62: a versatile multitasker takes on cancer.

Authors:  Jorge Moscat; Maria T Diaz-Meco
Journal:  Trends Biochem Sci       Date:  2012-03-15       Impact factor: 13.807

Review 3.  The atypical PKCs in inflammation: NF-κB and beyond.

Authors:  Maria T Diaz-Meco; Jorge Moscat
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

4.  Autophagy proteins regulate the secretory component of osteoclastic bone resorption.

Authors:  Carl J DeSelm; Brian C Miller; Wei Zou; Wandy L Beatty; Eline van Meel; Yoshifumi Takahata; Judith Klumperman; Sharon A Tooze; Steven L Teitelbaum; Herbert W Virgin
Journal:  Dev Cell       Date:  2011-11-04       Impact factor: 12.270

5.  Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone.

Authors:  Jumpei Teramachi; Hua Zhou; Mark A Subler; Yukiko Kitagawa; Deborah L Galson; David W Dempster; Jolene J Windle; Noriyoshi Kurihara; G David Roodman
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

6.  Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.

Authors:  Jumpei Teramachi; Yuki Nagata; Khalid Mohammad; Yuji Inagaki; Yasuhisa Ohata; Theresa Guise; Laëtitia Michou; Jacques P Brown; Jolene J Windle; Noriyoshi Kurihara; G David Roodman
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

7.  Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.

Authors:  Sonia D'Souza; Davide del Prete; Shunqian Jin; Quanhong Sun; Alissa J Huston; Flavia Esteve Kostov; Benedicte Sammut; Chang-Sook Hong; Judith L Anderson; Kenneth D Patrene; Shibing Yu; Chinavenmeni S Velu; Guozhi Xiao; H Leighton Grimes; G David Roodman; Deborah L Galson
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

8.  Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease.

Authors:  Jumpei Teramachi; Yuko Hiruma; Seiichi Ishizuka; Hisako Ishizuka; Jacques P Brown; Laëtitia Michou; Huiling Cao; Deborah L Galson; Mark A Subler; Hua Zhou; David W Dempster; Jolene J Windle; G David Roodman; Noriyoshi Kurihara
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

Review 9.  Paget's disease of bone-genetic and environmental factors.

Authors:  Frederick R Singer
Journal:  Nat Rev Endocrinol       Date:  2015-08-18       Impact factor: 43.330

10.  Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.

Authors:  Bruno Ferraz-de-Souza; Regina M Martin; Pedro Henrique S Correa
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.